Screener
Sarepta Therapeutics, Inc. SRPT Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpense.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | $6,207 | $5,254 | $12,567 | $15,444 |
| Accretion of investment discount, net | 955 | 1,887 | 1,597 | 4,125 |
| Interest expense | (21,508) | (5,228) | (43,221) | (9,731) |
| (Loss) gain on strategic investments | (448) | 36,721 | (2,160) | (54,007) |
| Other, net | (246) | (573) | 918 | (902) |
| Total other (expense) income, net | $(15,040) | $38,061 | $(30,299) | $(45,071) |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s interest expense?
- Sarepta Therapeutics, Inc. (SRPT) reported interest expense of -$21.51M in Q2 2026.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Sarepta Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude